Holen Sie sich die Stockscreener-App
15.36
0.92%
0.14
Handel nachbörslich:
15.33
-0.03
-0.20%
Schlusskurs vom Vortag:
$15.22
Offen:
$15.2
24-Stunden-Volumen:
533.47K
Relative Volume:
0.75
Marktkapitalisierung:
$196.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-121.02M
KGV:
-1.3641
EPS:
-11.26
Netto-Cashflow:
$-114.09M
1W Leistung:
-2.91%
1M Leistung:
-21.79%
6M Leistung:
-56.71%
1J Leistung:
-50.85%
1-Tages-Spanne:
$14.95
$15.50
1-Wochen-Bereich:
$14.95
$16.95
52-Wochen-Spanne:
$7.31
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
26 MAIN STREET, SUITE 101, CHATHAM, NY
Vergleichen Sie TNXP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
15.36 | 194.63M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Fibromyalgia and migraine drug maker to share brain research in SF - Stock Titan
Tonix highlights pathway for potential single-dose, seasonal protection against Lyme Disease - Proactive financial news
Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen - MarketBeat
Aug Gainers: How Tonix Pharmaceuticals Holding Corp stock reacts to inflationary pressuresMarket Activity Recap & Weekly Watchlist for Hot Stocks - moha.gov.vn
Tonix prices 615,025 shares at $16.26 in registered direct offering - Yahoo Finance
Tonix Pharma announces $20 million registered direct offering - MSN
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals secures $20 million investment from Point72 By Investing.com - Investing.com Nigeria
Tonix Pharma advances TNX-4800 Lyme disease program - MSN
Tonix Pharma Announces $20 Million Registered Direct Offering - TipRanks
Form 424B5 Tonix Pharmaceuticals - StreetInsider
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug - Asianet Newsable
What's Going On With Tonix Pharma Stock Monday?Tonix Pharmaceuticals (NASDAQ:TNXP) - Benzinga
Tonix Pharmaceuticals (TNXP) Secures $20 Million Investment - GuruFocus
Tonix Pharmaceuticals (TNXP) Unveils Updates on Lyme Disease Tre - GuruFocus
Tonix Pharmaceuticals Prices $20 Million Registered Direct Offering - marketscreener.com
Tonix Pharmaceuticals shares fall 6.4% premarket after co prices stock and warrant offering - marketscreener.com
Tonix Pharmaceuticals advances TNX-4800 for Lyme disease prevention - Investing.com
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering - GlobeNewswire
TNXPTonix Pharmaceut Latest Stock News & Market Updates - Stock Titan
Tonix Pharmaceuticals Announces Updates on TNX-4800 for Lyme Disease Prevention - TradingView — Track All Markets
Tonix Pharmaceuticals Advances TNX-4800 Development for Lyme Disease Prevention Planning Clinical Trials for Innovative Monoclonal Antibody Therapy - Quiver Quantitative
A single shot to prevent Lyme each year? Inside Tonix’s antibody plan - Stock Titan
Avoiding Lag: Real-Time Signals in (TNXP) Movement - Stock Traders Daily
TNXP (Tonix Pharmaceuticals Holding) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2025) - GuruFocus
Tonix licenses global rights to novel non-opioid neuropathic pain drug TNX-4900 - Proactive financial news
How rising interest rates impact Tonix Pharmaceuticals Holding Corp. stockSwing Trading Ideas & Explosive Capital Gains - bollywoodhelpline.com
Noble Financial Has Positive Outlook of TNXP FY2025 Earnings - MarketBeat
Published on: 2025-12-22 01:46:59 - Улправда
Recap Report: How rising interest rates impact Tonix Pharmaceuticals Holding Corp. stockQuarterly Risk Review & Low Risk High Win Rate Picks - Улправда
How Tonix Pharmaceuticals Holding Corp. stock benefits from tech adoptionJuly 2025 Summary & Low Risk Growth Stock Ideas - DonanımHaber
How Tonix Pharmaceuticals Holding Corp. stock reacts to inflationary pressuresMarket Growth Report & Verified Momentum Stock Watchlist - DonanımHaber
How analysts rate Tonix Pharmaceuticals Holding Corp. stock today2025 Technical Overview & Free Community Consensus Stock Picks - DonanımHaber
Why Tonix Pharmaceuticals Holding Corp. stock is trending among retail tradersAnalyst Upgrade & Safe Entry Trade Reports - Улправда
Tonix licenses S1R antagonist from Rutgers University - BioWorld MedTech
Tonix Pharma secures rights to TNX-4900 for pain management - MSN
Tonix Pharmaceuticals licenses worldwide rights to non-opioid pain drug By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals (TNXP) Secures Global Rights for Promising Pain Treatment - GuruFocus
Tonix Pharmaceuticals Licenses Non-Opioid Pain Medicine Candidate From Rutgers University - marketscreener.com
Tonix Pharma Secures Rights to TNX-4900 for Pain Management - TipRanks
Tonix Pharmaceuticals licenses worldwide rights to non-opioid pain drug - Investing.com
Tonix Pharmaceuticals Licenses TNX-4900 for Neuropathic Pain - TradingView — Track All Markets
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University - The Manila Times
Tonix Pharmaceuticals Licenses TNX-4900, a Non-Opioid Analgesic with Promising Efficacy and Safety Profile for Neuropathic Pain - Quiver Quantitative
Tonix Pharmaceuticals announces licensing TNX-4900 - marketscreener.com
Tonix Pharmaceuticals Holding Corp. Announces That It Licensed Exclusive Rights to Its Tnx-4900 Product Candidate for Chronic Neuropathic Pain from Rutgers University - marketscreener.com
[8-K] Tonix Pharmaceuticals Holding Corp. Reports Material Event | TNXP SEC FilingForm 8-K - Stock Titan
Tonix Pharmaceuticals Announces Licensing TNX-4900, a - GlobeNewswire
(TNXP) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Equities Analysts Offer Predictions for TNXP FY2025 Earnings - MarketBeat
Tonix Pharmaceuticals announces reverse stock split - MSN
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):